Developer docs
API playgroundTry for free, no card

Search company profiles

Spur Therapeutics

Full company profile

uuid0000fbd

Namestring
Spur Therapeutics
Legal namestring
Spur Therapeutics Limited
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Spur Therapeutics, formerly Freeline Therapeutics, is a clinical-stage biotechnology company developing adeno-associated virus (AAV) gene therapies for chronic diseases. Founded in 2015 and headquartered in Stevenage, United Kingdom with an additional office in New York, the company rebranded in June 2024 alongside a $50 million corporate financing from Syncona and the acquisition of SwanBio Therapeutics. Its pipeline is anchored by avigbagene parvec (FLT201), a Phase 3 registrational-stage gene therapy candidate encoding a rationally engineered glucocerebrosidase variant (GCase85) delivered via a proprietary AAV capsid to liver cells for Gaucher disease type 1. Two additional programs — SBT101 for adrenomyeloneuropathy (Phase 1 PROPEL trial) acquired via SwanBio, and SPR301 for GBA1 Parkinson's disease using an AAV9 capsid currently in IND-enabling studies — extend the platform into CNS indications, and an early-stage research program targets severe chronic heart failure.

The company's underlying technology centers on optimized gene therapy components: a GCase85 enzyme with substantially extended half-life versus wild-type, enabling deeper tissue penetration including bone and lung; proprietary AAV capsids engineered for higher transduction efficiency at lower doses; and tissue-selective promoters. Spur has received orphan drug designation for FLT201 in both the U.S. and EU and reported two-year Phase 1/2 follow-up data in which all five evaluable patients discontinued standard enzyme replacement or substrate reduction therapy while maintaining stable or improved disease biomarkers.

Spur Therapeutics operates a pre-revenue clinical-stage business model. The company does not yet commercialize any product and has not publicly disclosed pricing. Future revenue is expected to derive from one-time commercialization of approved gene therapies, distributed initially through qualified clinical trial sites and, upon approval, through specialty treatment centers and specialty pharmacies. Manufacturing at scale is outsourced to CDMOs with FDA/EMA-compliant quality systems, while CMC and preclinical activities are retained in-house. The company engages in enterprise-style GTM: scientific conference presentations, investor relations outreach, and direct engagement with researchers, clinicians, patient advocacy groups, and global regulators to advance clinical programs.

Short descriptiontext

Spur Therapeutics is a clinical-stage biotechnology company developing AAV gene therapies for chronic diseases, anchored by avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, with additional programs in adrenomyeloneuropathy, GBA1 Parkinson's disease, and heart failure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersStevenage, United Kingdom
HQ citystring
Stevenage
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV gene therapy, lysosomal storage disorders, clinical-stage biotechnology, Gaucher disease treatment, neurological gene therapy
Industry4 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Gene Therapy
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company developing gene therapies for chronic diseases. Revenue will be generated through commercialization of approved gene therapy products once clinical trials are completed and regulatory approvals are obtained.

spurtherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus (AAV) gene therapies for chronic debilitating diseases. Its pipeline includes avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, SBT101 in Phase 1 for adrenoleukodystrophy, and SPR301 in IND-enabling studies for GBA1 Parkinson's disease. The company uses proprietary AAV capsids and a rationally engineered GCase85 enzyme to deliver single-dose, disease-modifying treatments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • All five evaluable patients discontinued standard enzyme replacement or substrate reduction therapies while maintaining stable or improved disease biomarkers for over one year
+3 more records
Product overview1 text field

Spur Therapeutics is a clinical-stage biotechnology company developing gene therapies for chronic diseases. The company's portfolio includes three gene therapy candidates: avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, SBT101 in Phase 1 for adrenoleukodystrophy (AMN), and SPR301 in IND-enabling stage for GBA1 Parkinson's disease. Additionally, the company has an early-stage program in severe chronic heart failure. All candidates use AAV-based delivery systems with engineered enzymes (GCase85) designed for improved stability and tissue penetration. The company was formerly known as Freeline and rebranded in June 2024 after acquiring SwanBio Therapeutics.

Product and service4 records
1Avigbagene parvec (FLT201)
CategoryGene therapy candidate
Description

Clinical-stage AAV gene therapy candidate for Gaucher disease type 1 encoding a rationally engineered GCase85 enzyme variant with increased half-life. Designed as a one-time treatment to potentially stop or reverse disease progression by delivering sustained GCase enzyme expression via an AAV capsid to liver cells.

2SBT101
CategoryGene therapy candidate
Description

Gene therapy candidate for X-linked adrenoleukodystrophy (adrenomyeloneuropathy/AMN). Currently in Phase 1 clinical trial (PROPEL) evaluating safety in adult males.

3SPR301
CategoryGene therapy candidate
Description

Gene therapy development candidate for GBA1 Parkinson's disease. Uses AAV9 capsid to deliver rationally engineered GCase85 enzyme, demonstrating substantially higher GCase activity and greater alpha-synuclein reduction compared to wildtype GCase in preclinical studies.

4Severe Chronic Heart Failure Program
CategoryResearch program
Description

Early-stage gene therapy research program leveraging cardioprotective proteins for cardiovascular diseases, targeting a severe subset of chronic heart failure to help stop disease progression.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Spur Therapeutics acquired SwanBio Therapeutics, adding a gene therapy program for adrenoleukodystrophy (adrenomyeloneuropathy) and strengthening CNS expertise. This acquisition expanded the pipeline to include SBT101 program for AMN.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

For clinical and commercial supplies, Spur partners with CDMOs with quality systems compliant with FDA and EMA requirements. The company has in-house labs with CMC capabilities for preclinical drug development but outsources manufacturing at scale to external partners.

3Researchers and Clinicians Worldwide
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Spur works with researchers and clinicians around the world, peer companies in the healthcare industry, and patients and advocacy groups to advance gene therapy research and bring more impact to more people.

spurtherapeutics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborates with patients and advocacy groups as part of the company's mission to advance gene therapy and bring transformative medicines to patients who need them.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

uniQure is a clinical-stage gene therapy company developing AAV-based therapies for rare and CNS diseases, including a late-stage hemophilia B program. It is directly comparable to Spur in technology platform (AAV), clinical stage, and rare disease focus.

TypeDirect peer
Description

Regenxbio is a clinical-stage AAV gene therapy company with proprietary NAV Technology Platform for capsid delivery, advancing multiple internal and partnered programs across rare and prevalent diseases. It directly competes as an AAV platform peer.

TypeDirect peer
Description

Sarepta is a commercial-stage gene therapy company with approved AAV-based products (Elevidys, Zolgensma) for Duchenne muscular dystrophy and spinal muscular atrophy. It is directly comparable in AAV gene therapy modality and rare disease focus, though more advanced commercially.

TypeDirect peer
Description

Voyager Therapeutics is a clinical-stage gene therapy company developing AAV-based therapies primarily for CNS diseases including Parkinson's and ALS, using proprietary capsid engineering. It is directly comparable in CNS AAV delivery and platform-based gene therapy approach.

TypeDirect peer
Description

Taysha is a clinical-stage AAV gene therapy company focused on CNS and rare diseases, with multiple programs in clinical and preclinical development. It is comparable in AAV technology, clinical stage, and rare disease/CNS therapeutic focus.

TypeDirect peer
Description

Lexeo Therapeutics is a clinical-stage gene therapy company developing AAV-based therapies for cardiovascular and CNS diseases. It is directly comparable given Spur's own cardiovascular program and CNS pipeline focus.

TypeDirect peer
Description

Solid Biosciences is a clinical-stage AAV gene therapy company developing treatments for Duchenne muscular dystrophy and other rare diseases. It is directly comparable in AAV technology platform, clinical stage, and rare disease focus.

TypeDirect peer
Description

Prevail Therapeutics was a clinical-stage AAV gene therapy company focused on neurodegenerative diseases (Parkinson's, GBA1 programs, lysosomal storage disorders) before being acquired by Eli Lilly. It is highly comparable to Spur's GBA1 Parkinson's program and lysosomal storage disease focus.

TypeBroad incumbent
Description

BioMarin is a commercial-stage rare disease biotech with approved enzyme replacement therapies and a gene therapy pipeline including valoctocogene roxaparvovec for hemophilia A. It is a broader incumbent with overlapping rare disease expertise and gene therapy commercialization capabilities.

TypeBroad incumbent
Description

Pfizer is a large pharmaceutical company with an active gene therapy portfolio (including Beqvez for hemophilia B) and significant rare disease infrastructure. Spur's CEO Michael Parini previously held senior global roles at Pfizer, and it represents a potential strategic partner or acquirer with overlapping therapeutic interests.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spur Therapeutics

Spur Therapeutics is a clinical-stage biotechnology company developing AAV gene therapies for chronic diseases, anchored by avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, with additional programs in adrenomyeloneuropathy, GBA1 Parkinson's disease, and heart failure.

What Spur Therapeutics does

Spur Therapeutics, formerly Freeline Therapeutics, is a clinical-stage biotechnology company developing adeno-associated virus (AAV) gene therapies for chronic diseases. Founded in 2015 and headquartered in Stevenage, United Kingdom with an additional office in New York, the company rebranded in June 2024 alongside a $50 million corporate financing from Syncona and the acquisition of SwanBio Therapeutics. Its pipeline is anchored by avigbagene parvec (FLT201), a Phase 3 registrational-stage gene therapy candidate encoding a rationally engineered glucocerebrosidase variant (GCase85) delivered via a proprietary AAV capsid to liver cells for Gaucher disease type 1. Two additional programs — SBT101 for adrenomyeloneuropathy (Phase 1 PROPEL trial) acquired via SwanBio, and SPR301 for GBA1 Parkinson's disease using an AAV9 capsid currently in IND-enabling studies — extend the platform into CNS indications, and an early-stage research program targets severe chronic heart failure.

The company's underlying technology centers on optimized gene therapy components: a GCase85 enzyme with substantially extended half-life versus wild-type, enabling deeper tissue penetration including bone and lung; proprietary AAV capsids engineered for higher transduction efficiency at lower doses; and tissue-selective promoters. Spur has received orphan drug designation for FLT201 in both the U.S. and EU and reported two-year Phase 1/2 follow-up data in which all five evaluable patients discontinued standard enzyme replacement or substrate reduction therapy while maintaining stable or improved disease biomarkers.

Spur Therapeutics operates a pre-revenue clinical-stage business model. The company does not yet commercialize any product and has not publicly disclosed pricing. Future revenue is expected to derive from one-time commercialization of approved gene therapies, distributed initially through qualified clinical trial sites and, upon approval, through specialty treatment centers and specialty pharmacies. Manufacturing at scale is outsourced to CDMOs with FDA/EMA-compliant quality systems, while CMC and preclinical activities are retained in-house. The company engages in enterprise-style GTM: scientific conference presentations, investor relations outreach, and direct engagement with researchers, clinicians, patient advocacy groups, and global regulators to advance clinical programs.

Spur Therapeutics firmographics

Firmographics
Name
Spur Therapeutics
Legal name
Spur Therapeutics Limited
Website
https://spurtherapeutics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
251–500 employees
Short description
Spur Therapeutics is a clinical-stage biotechnology company developing AAV gene therapies for chronic diseases, anchored by avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, with additional programs in adrenomyeloneuropathy, GBA1 Parkinson's disease, and heart failure.
Ownership category
akta.pro rank

Spur Therapeutics industry classification

Industry
Product category
Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • AAV gene therapy
  • Lysosomal storage disorders
  • Clinical-stage biotechnology
  • Gaucher disease treatment
  • Neurological gene therapy

Where Spur Therapeutics is headquartered

Location

Headquarters

HQ city
Stevenage
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Spur Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Gene Therapy Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing gene therapies for chronic diseases. Revenue will be generated through commercialization of approved gene therapy products once clinical trials are completed and regulatory approvals are obtained.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Spur Therapeutics product offering

Product offering

Core offering

Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus (AAV) gene therapies for chronic debilitating diseases. Its pipeline includes avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, SBT101 in Phase 1 for adrenoleukodystrophy, and SPR301 in IND-enabling studies for GBA1 Parkinson's disease. The company uses proprietary AAV capsids and a rationally engineered GCase85 enzyme to deliver single-dose, disease-modifying treatments.

Product overview

Spur Therapeutics is a clinical-stage biotechnology company developing gene therapies for chronic diseases. The company's portfolio includes three gene therapy candidates: avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, SBT101 in Phase 1 for adrenoleukodystrophy (AMN), and SPR301 in IND-enabling stage for GBA1 Parkinson's disease. Additionally, the company has an early-stage program in severe chronic heart failure. All candidates use AAV-based delivery systems with engineered enzymes (GCase85) designed for improved stability and tissue penetration. The company was formerly known as Freeline and rebranded in June 2024 after acquiring SwanBio Therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Avigbagene parvec (FLT201) Clinical-stage AAV gene therapy candidate for Gaucher disease type 1 encoding a rationally engineered GCase85 enzyme variant with increased half-life. Designed as a one-time treatment to potentially stop or reverse disease progression by delivering sustained GCase enzyme expression via an AAV capsid to liver cells.
  • SBT101 Gene therapy candidate for X-linked adrenoleukodystrophy (adrenomyeloneuropathy/AMN). Currently in Phase 1 clinical trial (PROPEL) evaluating safety in adult males.
  • SPR301 Gene therapy development candidate for GBA1 Parkinson's disease. Uses AAV9 capsid to deliver rationally engineered GCase85 enzyme, demonstrating substantially higher GCase activity and greater alpha-synuclein reduction compared to wildtype GCase in preclinical studies.
  • Severe Chronic Heart Failure Program Early-stage gene therapy research program leveraging cardioprotective proteins for cardiovascular diseases, targeting a severe subset of chronic heart failure to help stop disease progression.

Quantifiable outcome

  • All five evaluable patients discontinued standard enzyme replacement or substrate reduction therapies while maintaining stable or improved disease biomarkers for over one year
  • +3 more outcomes

Companies that use Spur Therapeutics

Customer profile

Segments4 records

Ideal customer profiles2 records

Spur Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Spur Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • SwanBio TherapeuticscoreStrategic or Co-development Partner · 1 January 2024Spur Therapeutics acquired SwanBio Therapeutics, adding a gene therapy program for adrenoleukodystrophy (adrenomyeloneuropathy) and strengthening CNS expertise. This acquisition expanded the pipeline to include SBT101 program for AMN.
  • Contract Development and Manufacturing Organizations (CDMOs)coreImplementation/ SI/ Consulting PartnerFor clinical and commercial supplies, Spur partners with CDMOs with quality systems compliant with FDA and EMA requirements. The company has in-house labs with CMC capabilities for preclinical drug development but outsources manufacturing at scale to external partners.
  • Researchers and Clinicians WorldwideminorStrategic or Co-development PartnerSpur works with researchers and clinicians around the world, peer companies in the healthcare industry, and patients and advocacy groups to advance gene therapy research and bring more impact to more people.
  • Patients and Advocacy GroupsminorStrategic or Co-development PartnerCollaborates with patients and advocacy groups as part of the company's mission to advance gene therapy and bring transformative medicines to patients who need them.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Spur Therapeutics competitors and assessment

Company assessment

Direct peers

  • uniQure: uniQure is a clinical-stage gene therapy company developing AAV-based therapies for rare and CNS diseases, including a late-stage hemophilia B program. It is directly comparable to Spur in technology platform (AAV), clinical stage, and rare disease focus.
  • Regenxbio: Regenxbio is a clinical-stage AAV gene therapy company with proprietary NAV Technology Platform for capsid delivery, advancing multiple internal and partnered programs across rare and prevalent diseases. It directly competes as an AAV platform peer.
  • Sarepta Therapeutics: Sarepta is a commercial-stage gene therapy company with approved AAV-based products (Elevidys, Zolgensma) for Duchenne muscular dystrophy and spinal muscular atrophy. It is directly comparable in AAV gene therapy modality and rare disease focus, though more advanced commercially.
  • Voyager Therapeutics: Voyager Therapeutics is a clinical-stage gene therapy company developing AAV-based therapies primarily for CNS diseases including Parkinson's and ALS, using proprietary capsid engineering. It is directly comparable in CNS AAV delivery and platform-based gene therapy approach.
  • Taysha Gene Therapies: Taysha is a clinical-stage AAV gene therapy company focused on CNS and rare diseases, with multiple programs in clinical and preclinical development. It is comparable in AAV technology, clinical stage, and rare disease/CNS therapeutic focus.
  • Lexeo Therapeutics: Lexeo Therapeutics is a clinical-stage gene therapy company developing AAV-based therapies for cardiovascular and CNS diseases. It is directly comparable given Spur's own cardiovascular program and CNS pipeline focus.
  • Solid Biosciences: Solid Biosciences is a clinical-stage AAV gene therapy company developing treatments for Duchenne muscular dystrophy and other rare diseases. It is directly comparable in AAV technology platform, clinical stage, and rare disease focus.
  • Prevail Therapeutics: Prevail Therapeutics was a clinical-stage AAV gene therapy company focused on neurodegenerative diseases (Parkinson's, GBA1 programs, lysosomal storage disorders) before being acquired by Eli Lilly. It is highly comparable to Spur's GBA1 Parkinson's program and lysosomal storage disease focus.

Broad incumbents

  • BioMarin Pharmaceutical: BioMarin is a commercial-stage rare disease biotech with approved enzyme replacement therapies and a gene therapy pipeline including valoctocogene roxaparvovec for hemophilia A. It is a broader incumbent with overlapping rare disease expertise and gene therapy commercialization capabilities.
  • Pfizer: Pfizer is a large pharmaceutical company with an active gene therapy portfolio (including Beqvez for hemophilia B) and significant rare disease infrastructure. Spur's CEO Michael Parini previously held senior global roles at Pfizer, and it represents a potential strategic partner or acquirer with overlapping therapeutic interests.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Spur Therapeutics social profiles

Digital presence

Spur Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spur Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Spur Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spur Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spur Therapeutics

What does Spur Therapeutics do?

Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus (AAV) gene therapies for chronic debilitating diseases. Its pipeline includes avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, SBT101 in Phase 1 for adrenoleukodystrophy, and SPR301 in IND-enabling studies for GBA1 Parkinson's disease. The company uses proprietary AAV capsids and a rationally engineered GCase85 enzyme to deliver single-dose, disease-modifying treatments.

Is Spur Therapeutics a public or private company?

Spur Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Spur Therapeutics founded?

Spur Therapeutics was founded in 2015. It employs 251 to 500 people.

Where is Spur Therapeutics based?

Spur Therapeutics is headquartered in Stevenage, United Kingdom, in the Europe region.

How does Spur Therapeutics make money?

One revenue line is on record: gene Therapy Development and Commercialization.

Who are Spur Therapeutics's main competitors?

Direct peers on record are uniQure, Regenxbio, Sarepta Therapeutics, Voyager Therapeutics, Taysha Gene Therapies, Lexeo Therapeutics, Solid Biosciences and Prevail Therapeutics. Broad incumbents are BioMarin Pharmaceutical and Pfizer.

Does Spur Therapeutics have an API?

No public API is recorded for Spur Therapeutics.

What industry is Spur Therapeutics in?

Spur Therapeutics's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSpur Therapeutics Announces Executive TransitionsSpur Therapeutics announced CEO Michael Parini will become chair of the board effective July 31, 2026, and CSO Henning Stennicke will become COO on August 1. Samantha Roberts, MD, PhD, will join as a board director. The company's lead asset FLT201 is in Phase 3 development for Gaucher disease.CGTLiveAround the Helix: Cell and Gene Therapy Company Updates – February 4, 2026CGTLive's weekly roundup covered multiple cell and gene therapy developments, including Ocugen's OCU410ST gene therapy showing a +6-letter BCVA improvement in a phase 1 trial for a rare eye disease, and Ultragenyx resubmitting its BLA for UX111 (rebisufligene etisparvovec) to the FDA with longer-term neurologic benefit data to support accelerated approval for MPS IIIA. Additional updates included Taysha Gene Therapies dosing the first patient in the phase 3 REVEAL trial for Rett syndrome treatment, Spur Therapeutics reporting sustained decreases in a Gaucher disease biomarker at 2 years post-treatment, Wave Life Sciences regaining full rights to WVE-006 from GSK for AATD, and Anixa Biosciences receiving the nonproprietary name liraltagene autoleucel for its ovarian cancer CAR-T therapy.GlobeNewswireSpur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher Disease Type 1Spur Therapeutics presented new data from GALILEO-1 and GALILEO-2 trials of FLT201, an investigational gene therapy for Gaucher disease type 1, showing improvements in bone disease. The data indicate reduced bone marrow burden and improved bone mineral density, with reversible steroid-related bone effects. The company plans to demonstrate this profile in a larger dataset through its Phase 3 trial.GlobeNewswireSpur Therapeutics To Present New Clinical Data on FLT201 for Gaucher Disease during the IWGGD 2026 SymposiumSpur Therapeutics will present new clinical data on its FLT201 gene therapy for Gaucher disease type 1 at the IWGGD 2026 symposium in Trieste, Italy, May 3-6. The oral presentation covers two-year follow-up from GALILEO-1 and GALILEO-2 trials, with posters on GALILEO-3 and bone health markers.The Manila TimesSpur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™Spur Therapeutics announced positive Phase 1/2 data for its gene therapy candidate avigbagene parvec targeting Gaucher disease, demonstrating safety, biomarker improvements, and clinical benefits over two years. The company initiated a Phase 3 trial based on these results, aiming to reduce treatment burdens for patients.GlobeNewswireSpur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™Spur Therapeutics presented two-year follow-up data on avigbagene parvec (FLT201) for Gaucher disease, showing sustained clinical benefit and lyso-Gb1 reductions of 53-94% in responsive patients. The company initiated a Phase 3 trial, with alignment to the FDA on a single-arm design for potential accelerated approval.The Manila TimesSpur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium™Spur Therapeutics announced it will present updated two-year clinical data from its Phase 1/2 GALILEO-1 and GALILEO-2 trials of FLT201, a Phase 3 gene therapy candidate for Type 1 Gaucher disease, at the 22nd Annual WORLDSymposium in San Diego on February 5, 2026. The presentations will include platform and poster sessions featuring data from adult participants treated with avigbagene parvec. The announcement highlights continued clinical progress for the company's lead gene therapy program.GlobeNewswireSpur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium™Spur Therapeutics announced the presentation of clinical data from its Phase 1/2 and Phase 3 trials of FLT201, a gene therapy for Type 1 Gaucher disease, at the WORLDSymposium 2026 in San Diego. Multiple poster sessions will showcase two-year follow-up results and biomarker data.The Globe and MailAdrenomyeloneuropathy Market: Epidemiology, Emerging Therapies, and Key Companies – DelveInsight | Featuring Minoryx Therapeutics, Spur Therapeutics, Viking TherapeuticsViking Therapeutics reported positive Phase Ib data for VK0214 in October 2024, and DelveInsight released a market report on adrenomyeloneuropathy. The report covers epidemiology and emerging therapies, noting the US held 45% of the 7MM market in 2024, with about 3,500 diagnosed cases. Growth is expected as new therapies develop.The Manila TimesSpur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual CongressSpur Therapeutics presented updated Phase 1/2 data on avigbagene parvec (FLT201) at ESGCT 32nd Annual Congress, showing sustained clinical benefit and favorable safety up to 23 months after a single low dose. Four patients remained off chronic therapy, with stable or improved outcomes. The company plans to initiate a Phase 3 trial in the first half of 2026.